Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Retained Earnings (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Retained Earnings for 2 consecutive years, with -$418.8 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 9.13% to -$418.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$418.8 million through Dec 2025, down 9.13% year-over-year, with the annual reading at -$418.8 million for FY2025, 9.13% down from the prior year.
  • Retained Earnings hit -$418.8 million in Q4 2025 for Xilio Therapeutics, up from -$429.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$342.7 million in Q1 2024 to a low of -$429.1 million in Q3 2025.